Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
November 08 2024 - 3:47PM
UK Regulatory
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from
Novo Holdings A/S under the 2024 share repurchase programme
Bagsværd, Denmark, 8 November 2024 – Today,
Novo Nordisk A/S has entered into an agreement to purchase
6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00
from Novo Holdings A/S. The transaction is part of Novo Nordisk
A/S’ 2024 share repurchase programme of up to a total of DKK 20
billion to be executed during a 12-month period beginning 6
February 2024. The transaction price is DKK 750.42 per share and
has been calculated as the three-day volume weighted average market
price from 6 November 2024 to 8 November 2024 in the open window
following the announcement of Novo Nordisk A/S’ quarterly financial
results.
Prior to the sale of B shares, Novo Holdings A/S’ ownership of
Novo Nordisk A/S was 28.2% of the share capital and 77.3% of the
votes. Following the transaction, Novo Holdings A/S owns
1,074,872,000 A shares of DKK 0.10 and 177,560,500 B shares of DKK
0.10, corresponding to 28.1% of the capital and 77.3% of the votes
in Novo Nordisk A/S.
The transaction is in line with the announcement on 31 January
2024 that Novo Holdings A/S intends to maintain its ownership of
Novo Nordisk A/S’ share capital around 28%.
In addition, transactions related to Novo Nordisk’s incentive
programmes have resulted in a net transfer from Novo Nordisk of
183,245 B shares in the period from 6 November 2024 to 8 November
2024.
With the transactions stated above, Novo Nordisk A/S owns a
total of 21,348,485 B shares of DKK 0.10, corresponding to 0.5% of
the share capital, as treasury shares. The total number of A and B
shares in the company is 4,465,000,000 of DKK 0.10 including
treasury shares.
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 72,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram,
X, LinkedIn and
YouTube.
Contacts for further information
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Sina
Meyer
+45 3079 6656 azey@novonordisk.com
|
Ida
Schaap Melvold
+45 3077 5649 idmg@novonordisk.com
|
Frederik
Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
|
|
Company announcement No 84 / 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Nov 2023 to Nov 2024